Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001213900-25-033322
Filing Date
2025-04-18
Accepted
2025-04-18 15:05:14
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS ea0237916-defa14a_orukathera.htm DEFA14A 17420
2 GRAPHIC image_001.jpg GRAPHIC 724128
3 GRAPHIC image_002.jpg GRAPHIC 513567
  Complete submission text file 0001213900-25-033322.txt   1723479
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 25850272
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)